Schonfeld Strategic Advisors LLC Reduces Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Schonfeld Strategic Advisors LLC lowered its stake in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 30.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,058,100 shares of the company’s stock after selling 457,800 shares during the period. Schonfeld Strategic Advisors LLC owned 3.16% of Reviva Pharmaceuticals worth $1,915,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock worth $401,000 after acquiring an additional 42,376 shares during the last quarter. Drive Wealth Management LLC purchased a new position in shares of Reviva Pharmaceuticals in the fourth quarter worth about $36,000. EMC Capital Management lifted its holdings in shares of Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the period. Raymond James Financial Inc. purchased a new stake in Reviva Pharmaceuticals in the fourth quarter valued at approximately $25,000. Finally, XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the 4th quarter worth approximately $45,000. 63.18% of the stock is currently owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Trading Down 1.7 %

NASDAQ RVPH opened at $0.85 on Tuesday. The stock has a market cap of $39.84 million, a PE ratio of -0.77 and a beta of 0.08. Reviva Pharmaceuticals Holdings, Inc. has a twelve month low of $0.49 and a twelve month high of $4.28. The stock has a fifty day simple moving average of $0.92 and a 200-day simple moving average of $1.37.

Reviva Pharmaceuticals (NASDAQ:RVPH) last released its quarterly earnings results on Monday, March 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Research analysts predict that Reviva Pharmaceuticals Holdings, Inc. will post -0.97 EPS for the current year.

Wall Street Analyst Weigh In

RVPH has been the topic of a number of research reports. D. Boral Capital reiterated a “buy” rating and issued a $8.00 price objective on shares of Reviva Pharmaceuticals in a research note on Thursday, April 24th. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, January 10th. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. HC Wainwright dropped their target price on Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Finally, Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 price target on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.